{ "name": "Research peptide compound profiles", "description": "For each research compound in the Primara Labs catalogue: class, receptor targets or pathway, mechanism in plain language, and PubChem identity (CID, formula, weight, CAS, sequence), each field sourced and dated.", "source": "https://www.primaralabs.com/research/evidence", "lastUpdated": "2026-09-23", "licence": "Free to reuse with a link to the source page.", "schema": [ { "key": "compound", "type": "string", "description": "Compound name." }, { "key": "compoundId", "type": "string", "description": "Anchor on /research/evidence." }, { "key": "compoundClass", "type": "string", "description": "Compound class." }, { "key": "targets", "type": "string", "description": "Receptor targets or pathway." }, { "key": "mechanism", "type": "string", "description": "Mechanism in plain language, from the row source." }, { "key": "pubchemCid", "type": "integer", "description": "PubChem compound identifier." }, { "key": "pubchemCidSourceUrl", "type": "url", "description": "Where pubchem cid was read." }, { "key": "pubchemCidCheckedOn", "type": "date", "description": "ISO date pubchem cid was read." }, { "key": "molecularFormula", "type": "string", "description": "Molecular formula as PubChem gives it." }, { "key": "molecularFormulaSourceUrl", "type": "url", "description": "Where formula was read." }, { "key": "molecularFormulaCheckedOn", "type": "date", "description": "ISO date formula was read." }, { "key": "molecularWeight", "type": "number", "description": "g/mol as PubChem gives it." }, { "key": "molecularWeightSourceUrl", "type": "url", "description": "Where molecular weight was read." }, { "key": "molecularWeightCheckedOn", "type": "date", "description": "ISO date molecular weight was read." }, { "key": "cas", "type": "string", "description": "CAS number, only where PubChem gives exactly one." }, { "key": "casSourceUrl", "type": "url", "description": "Where cas was read." }, { "key": "casCheckedOn", "type": "date", "description": "ISO date cas was read." }, { "key": "sequence", "type": "string", "description": "Amino acid sequence where PubChem gives one." }, { "key": "sequenceSourceUrl", "type": "url", "description": "Where sequence was read." }, { "key": "sequenceCheckedOn", "type": "date", "description": "ISO date sequence was read." }, { "key": "identityNote", "type": "string", "description": "Why an identity field is not published, where one is not." }, { "key": "sourceUrl", "type": "url", "description": "The primary source the row was read from." }, { "key": "checkedOn", "type": "date", "description": "ISO date the source was last read." } ], "rowCount": 16, "rows": [ { "compound": "Retatrutide", "compoundId": "retatrutide", "compoundClass": "Peptide triple hormone receptor agonist", "targets": "GIP, GLP-1 and glucagon receptors", "mechanism": "Retatrutide is a single peptide that activates three receptors: GIP, GLP-1 and glucagon. Lilly describes it as a first-in-class triple hormone receptor agonist.", "pubchemCid": null, "pubchemCidSourceUrl": null, "pubchemCidCheckedOn": null, "molecularFormula": null, "molecularFormulaSourceUrl": null, "molecularFormulaCheckedOn": null, "molecularWeight": null, "molecularWeightSourceUrl": null, "molecularWeightCheckedOn": null, "cas": null, "casSourceUrl": null, "casCheckedOn": null, "sequence": null, "sequenceSourceUrl": null, "sequenceCheckedOn": null, "identityNote": "PubChem holds no compound record under the name retatrutide (checked 23 September 2026), and the originating paper is not open access, so formula, weight, CAS and sequence are not published here.", "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional", "checkedOn": "2026-09-23" }, { "compound": "Tirzepatide", "compoundId": "tirzepatide", "compoundClass": "Peptide dual incretin receptor agonist", "targets": "GIP and GLP-1 receptors", "mechanism": "Tirzepatide is a single peptide that activates two receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1.", "pubchemCid": 166567236, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/166567236", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C225H348N48O68", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/166567236", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 4813, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/166567236", "molecularWeightCheckedOn": "2026-09-23", "cas": "2023788-19-2", "casSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/166567236", "casCheckedOn": "2026-09-23", "sequence": null, "sequenceSourceUrl": null, "sequenceCheckedOn": null, "identityNote": null, "sourceUrl": "https://doi.org/10.1056/NEJMoa2206038", "checkedOn": "2026-09-23" }, { "compound": "Semaglutide", "compoundId": "semaglutide", "compoundClass": "GLP-1 analogue", "targets": "GLP-1 receptor", "mechanism": "Semaglutide is a GLP-1 analogue that selectively binds to and activates the GLP-1 receptor, the target of native GLP-1.", "pubchemCid": 56843331, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/56843331", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C187H291N45O59", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/56843331", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 4114, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/56843331", "molecularWeightCheckedOn": "2026-09-23", "cas": "910463-68-2", "casSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/56843331", "casCheckedOn": "2026-09-23", "sequence": null, "sequenceSourceUrl": null, "sequenceCheckedOn": null, "identityNote": null, "sourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42bdd912-2393-44c4-b7e0-47672ca28991", "checkedOn": "2026-09-23" }, { "compound": "BPC-157", "compoundId": "bpc-157", "compoundClass": "Synthetic pentadecapeptide", "targets": "No defined receptor; pathways proposed from animal and cell work", "mechanism": "BPC-157 is a synthetic 15-amino-acid peptide. A 2025 systematic review summarises animal and cell studies as showing raised growth hormone receptor expression, activation of pathways for cell growth and new blood vessel formation, and lower inflammatory signalling. No receptor has been identified, and the same review notes it is broken down quickly in the liver. None of these mechanisms has been shown in people.", "pubchemCid": 9941957, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9941957", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C62H98N16O22", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9941957", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 1419.5, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9941957", "molecularWeightCheckedOn": "2026-09-23", "cas": "137525-51-0", "casSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9941957", "casCheckedOn": "2026-09-23", "sequence": "GEPPPGKPADDAGLV", "sequenceSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9941957", "sequenceCheckedOn": "2026-09-23", "identityNote": null, "sourceUrl": "https://doi.org/10.1177/15563316251355551", "checkedOn": "2026-09-23" }, { "compound": "TB-500", "compoundId": "tb-500", "compoundClass": "Thymosin beta-4 related peptide", "targets": "Actin binding (the LKKTETQ sequence of thymosin beta-4)", "mechanism": "Thymosin beta-4 is a 43-amino-acid protein and the main actin-sequestering molecule in cells. Its central actin-binding sequence, LKKTETQ, is reported to promote cell migration, new blood vessel growth and wound healing, and TB-500 is described in the analytical literature as the acetylated form of that fragment. A 2024 cell study found the wound-healing activity came from a TB-500 breakdown product rather than TB-500 itself.", "pubchemCid": null, "pubchemCidSourceUrl": null, "pubchemCidCheckedOn": null, "molecularFormula": null, "molecularFormulaSourceUrl": null, "molecularFormulaCheckedOn": null, "molecularWeight": null, "molecularWeightSourceUrl": null, "molecularWeightCheckedOn": null, "cas": null, "casSourceUrl": null, "casCheckedOn": null, "sequence": null, "sequenceSourceUrl": null, "sequenceCheckedOn": null, "identityNote": "The catalogue listed the full 43-residue thymosin beta-4 sequence under the name TB-500, while the analytical literature identifies TB-500 as the fragment Ac-LKKTETQ, and the catalogue's formula matched neither PubChem record. Identity fields are withheld until the supplier confirms which molecule the vial contains.", "sourceUrl": "https://doi.org/10.1096/fj.09-142307", "checkedOn": "2026-09-23" }, { "compound": "GHK-Cu", "compoundId": "ghk-cu", "compoundClass": "Copper-binding tripeptide", "targets": "Copper binding; tissue remodelling enzymes (from cell and animal work)", "mechanism": "GHK is a tripeptide (glycine, histidine, lysine) found in human plasma, saliva and urine, and it binds copper. In laboratory work it stimulates both the production and the breakdown of collagen and related skin matrix molecules, and adjusts the enzymes that remodel tissue. The evidence for these actions comes from cell and animal studies.", "pubchemCid": null, "pubchemCidSourceUrl": null, "pubchemCidCheckedOn": null, "molecularFormula": null, "molecularFormulaSourceUrl": null, "molecularFormulaCheckedOn": null, "molecularWeight": null, "molecularWeightSourceUrl": null, "molecularWeightCheckedOn": null, "cas": null, "casSourceUrl": null, "casCheckedOn": null, "sequence": "Gly-His-Lys, as a copper complex", "sequenceSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/73587", "sequenceCheckedOn": "2026-09-23", "identityNote": "PubChem records the GHK-copper complex under several formulas, so formula, weight and CAS are not published for the complex. The free tripeptide GHK is PubChem CID 73587.", "sourceUrl": "https://doi.org/10.1155/2015/648108", "checkedOn": "2026-09-23" }, { "compound": "KPV", "compoundId": "kpv", "compoundClass": "Tripeptide (alpha-MSH 11-13)", "targets": "PepT1 transporter uptake; NF-kB and MAP kinase inflammatory signalling (cell work)", "mechanism": "KPV is the last three amino acids of alpha-melanocyte-stimulating hormone. In cell studies it enters intestinal and immune cells through the peptide transporter PepT1 and dampens NF-kB and MAP kinase inflammatory signalling. A mouse study found its anti-inflammatory effect is unlikely to act through melanocortin receptors.", "pubchemCid": 125672, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/125672", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C16H30N4O4", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/125672", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 342.43, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/125672", "molecularWeightCheckedOn": "2026-09-23", "cas": "67727-97-3", "casSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/125672", "casCheckedOn": "2026-09-23", "sequence": "Lys-Pro-Val", "sequenceSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/125672", "sequenceCheckedOn": "2026-09-23", "identityNote": null, "sourceUrl": "https://doi.org/10.1053/j.gastro.2007.10.026", "checkedOn": "2026-09-23" }, { "compound": "NAD+", "compoundId": "nad", "compoundClass": "Coenzyme (dinucleotide)", "targets": "Cellular energy metabolism and redox reactions; cofactor for DNA-repair and metabolic enzymes", "mechanism": "NAD+ is a coenzyme central to cellular energy metabolism and redox balance, and a cofactor for enzymes involved in DNA repair and metabolism. Its levels fall with age, which is the rationale researchers give for supplementation. When infused into people it is cleared from plasma quickly and broken down by NAD-consuming enzymes, so how much reaches cells intact is unclear.", "pubchemCid": 5892, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/5892", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C21H27N7O14P2", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/5892", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 663.4, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/5892", "molecularWeightCheckedOn": "2026-09-23", "cas": null, "casSourceUrl": null, "casCheckedOn": null, "sequence": null, "sequenceSourceUrl": null, "sequenceCheckedOn": null, "identityNote": null, "sourceUrl": "https://doi.org/10.1007/s40256-025-00764-7", "checkedOn": "2026-09-23" }, { "compound": "MOTS-c", "compoundId": "mots-c", "compoundClass": "Mitochondrial-derived peptide", "targets": "Folate cycle and purine synthesis in skeletal muscle, activating AMPK (mouse and cell work)", "mechanism": "MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. In mouse and cell studies it acts mainly on skeletal muscle, where it inhibits the folate cycle and linked purine synthesis, which activates the energy sensor AMPK. In people, exercise raises the body's own MOTS-c levels; it has not been given to people in a published study.", "pubchemCid": 146675088, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/146675088", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C101H152N28O22S2", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/146675088", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 2174.6, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/146675088", "molecularWeightCheckedOn": "2026-09-23", "cas": "1627580-64-6", "casSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/146675088", "casCheckedOn": "2026-09-23", "sequence": "MRWQEMGYIFYPRKLR", "sequenceSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/146675088", "sequenceCheckedOn": "2026-09-23", "identityNote": null, "sourceUrl": "https://doi.org/10.1016/j.cmet.2015.02.009", "checkedOn": "2026-09-23" }, { "compound": "Tesamorelin", "compoundId": "tesamorelin", "compoundClass": "Growth hormone-releasing factor analogue", "targets": "GHRH receptor (pituitary)", "mechanism": "Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GHRH 1-44). It acts on the pituitary to increase basal and pulsatile growth hormone secretion, which in turn raises IGF-1.", "pubchemCid": 16137828, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/16137828", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C221H366N72O67S", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/16137828", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 5136, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/16137828", "molecularWeightCheckedOn": "2026-09-23", "cas": "218949-48-5", "casSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/16137828", "casCheckedOn": "2026-09-23", "sequence": "YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL, with an N-terminal trans-3-hexenoyl group", "sequenceSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/16137828", "sequenceCheckedOn": "2026-09-23", "identityNote": null, "sourceUrl": "https://doi.org/10.1007/s40262-014-0202-x", "checkedOn": "2026-09-23" }, { "compound": "CJC-1295", "compoundId": "cjc-1295", "compoundClass": "Growth hormone-releasing hormone analogue", "targets": "GHRH receptor (pituitary)", "mechanism": "CJC-1295 is a modified analogue of growth hormone-releasing hormone (GHRH 1-29). The form studied in people carries a reactive group that binds to albumin in the blood, which extends its half-life to several days and gives sustained rises in growth hormone and IGF-1.", "pubchemCid": null, "pubchemCidSourceUrl": null, "pubchemCidCheckedOn": null, "molecularFormula": null, "molecularFormulaSourceUrl": null, "molecularFormulaCheckedOn": null, "molecularWeight": null, "molecularWeightSourceUrl": null, "molecularWeightCheckedOn": null, "cas": null, "casSourceUrl": null, "casCheckedOn": null, "sequence": null, "sequenceSourceUrl": null, "sequenceCheckedOn": null, "identityNote": "The name CJC-1295 resolves in PubChem to the albumin-binding (DAC) form, while the catalogue's formula matched the form without DAC. Identity fields are withheld until the supplier confirms which form the vial contains.", "sourceUrl": "https://doi.org/10.1152/ajpendo.00201.2006", "checkedOn": "2026-09-23" }, { "compound": "Ipamorelin", "compoundId": "ipamorelin", "compoundClass": "Growth hormone secretagogue (pentapeptide)", "targets": "Ghrelin (GHS) receptor", "mechanism": "Ipamorelin is a synthetic five-amino-acid growth hormone secretagogue that acts on the ghrelin receptor to release growth hormone from the pituitary. In animal pharmacology it released growth hormone without raising ACTH or cortisol, which is why its developers called it selective.", "pubchemCid": 9831659, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9831659", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C38H49N9O5", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9831659", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 711.9, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9831659", "molecularWeightCheckedOn": "2026-09-23", "cas": "170851-70-4", "casSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9831659", "casCheckedOn": "2026-09-23", "sequence": "Aib-His-D-2Nal-D-Phe-Lys-NH2", "sequenceSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9831659", "sequenceCheckedOn": "2026-09-23", "identityNote": null, "sourceUrl": "https://doi.org/10.1530/eje.0.1390552", "checkedOn": "2026-09-23" }, { "compound": "Bremelanotide", "compoundId": "bremelanotide", "compoundClass": "Melanocortin receptor agonist (cyclic heptapeptide)", "targets": "Melanocortin receptors, chiefly MC3R and MC4R", "mechanism": "Bremelanotide is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone that acts as an agonist at melanocortin receptors, chiefly MC3R and MC4R. Investigators link MC4R agonism to its effects on sexual desire; MC4R also regulates appetite, which is why it was studied for food intake.", "pubchemCid": 9941379, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9941379", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C50H68N14O10", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9941379", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 1025.2, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9941379", "molecularWeightCheckedOn": "2026-09-23", "cas": "189691-06-3", "casSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9941379", "casCheckedOn": "2026-09-23", "sequence": "Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH", "sequenceSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9941379", "sequenceCheckedOn": "2026-09-23", "identityNote": null, "sourceUrl": "https://doi.org/10.1111/j.1743-6109.2006.00268.x", "checkedOn": "2026-09-23" }, { "compound": "Semax", "compoundId": "semax", "compoundClass": "ACTH(4-10) analogue heptapeptide", "targets": "No defined human receptor; BDNF and trkB signalling in rat work", "mechanism": "Semax is a synthetic seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of ACTH. In rats it binds specific sites in the basal forebrain and raises BDNF and its receptor trkB. No defined receptor target in people is reported.", "pubchemCid": 9811102, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9811102", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C37H51N9O10S", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9811102", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 813.9, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9811102", "molecularWeightCheckedOn": "2026-09-23", "cas": "80714-61-0", "casSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9811102", "casCheckedOn": "2026-09-23", "sequence": "MEHFPGP", "sequenceSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/9811102", "sequenceCheckedOn": "2026-09-23", "identityNote": null, "sourceUrl": "https://doi.org/10.1111/j.1471-4159.2006.03658.x", "checkedOn": "2026-09-23" }, { "compound": "Selank", "compoundId": "selank", "compoundClass": "Synthetic heptapeptide", "targets": "Proposed GABA receptor modulation and enkephalinase inhibition (laboratory work)", "mechanism": "Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro). Laboratory and rat studies propose two mechanisms, allosteric modulation of GABA receptors and inhibition of the enzymes that break down enkephalins. Neither has been confirmed in human pharmacology studies.", "pubchemCid": 11765600, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/11765600", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C33H57N11O9", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/11765600", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 751.9, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/11765600", "molecularWeightCheckedOn": "2026-09-23", "cas": "129954-34-3", "casSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/11765600", "casCheckedOn": "2026-09-23", "sequence": "TKPRPGP", "sequenceSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/11765600", "sequenceCheckedOn": "2026-09-23", "identityNote": null, "sourceUrl": "https://doi.org/10.2174/0929866525666180925144642", "checkedOn": "2026-09-23" }, { "compound": "DSIP", "compoundId": "dsip", "compoundClass": "Nonapeptide", "targets": "Unknown; no gene, precursor or receptor identified", "mechanism": "Delta sleep-inducing peptide is a nine-amino-acid peptide first isolated from rabbit blood in 1977. No gene, precursor protein or receptor for it has been identified, so its mechanism of action is unknown, and a 2006 review describes its link to sleep as poorly characterised.", "pubchemCid": 68816, "pubchemCidSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/68816", "pubchemCidCheckedOn": "2026-09-23", "molecularFormula": "C35H48N10O15", "molecularFormulaSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/68816", "molecularFormulaCheckedOn": "2026-09-23", "molecularWeight": 848.8, "molecularWeightSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/68816", "molecularWeightCheckedOn": "2026-09-23", "cas": null, "casSourceUrl": null, "casCheckedOn": null, "sequence": "WAGGDASGE", "sequenceSourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/68816", "sequenceCheckedOn": "2026-09-23", "identityNote": null, "sourceUrl": "https://doi.org/10.1111/j.1471-4159.2006.03693.x", "checkedOn": "2026-09-23" } ] }